文献速递主动脉疾病

标准开窗腔内主动脉修复术后肾动脉支架并发症及其对肾功能的影响

Renal Stent Complications and Impact on Renal Function after Standard Fenestrated Endovascular Aneurysm Repair.
PubMed 文献 · Ann Vasc Surg · 2020-11-27

单中心回顾性分析2012至2018年114例使用Cook ZFEN装置行择期开窗腔内主动脉修复术(fEVAR)的患者,193条肾动脉置入支架。

要点

  • fEVAR术后肾支架并发症发生率为12.3%,二次通畅率99.4%。
  • 肾支架并发症对肾功能无显著影响。
  • 较小原生肾动脉直径是支架通畅性丢失的独立危险因素。

核心结论

  • fEVAR治疗近肾主动脉瘤持久有效,二次通畅率极佳。
  • 肾支架并发症对肾功能无显著影响。
  • 较小原生肾动脉与支架并发症风险升高相关。

研究设计与样本

  • 单中心回顾性研究,纳入2012至2018年114例择期fEVAR患者,使用Cook ZFEN装置。
  • 共193条肾动脉置入支架(133枚Atrium iCAST,60枚Gore VBX)。
  • 技术成功率97.4%,平均随访23.3个月。

主要发现

  • 所有支架并发症均行血管内再干预,中位住院1天(0-10),技术成功率94.2%。
  • 估计一期通畅率24个月为92.1%,48个月为81.5%;末次随访二次通畅率99.4%。
  • 末次随访平均eGFR在有无肾并发症组间无显著差异(43.75 vs. 55.58 mL/min/1.73 m2,P=0.09)。

关键数值与推荐

  • 肾支架并发症定义为狭窄、闭塞、扭结、肾支架相关内漏及再干预。
  • eGFR采用MDRD公式估算。
  • 按CKD分期与基线比较,有无肾支架并发症组分别有81.4%和72.7%的患者肾脏疾病稳定或改善(P=0.51)。

临床怎么用

  • fEVAR术后需定期监测肾支架通畅性,尤其对于原生肾动脉直径较小的患者。
  • 肾支架并发症多可通过血管内再干预处理,住院时间短。
  • 肾支架并发症对肾功能影响有限,但需关注较小肾动脉等高危因素。

局限性

  • 单中心回顾性设计。
  • 样本量有限。
  • 缺乏长期随访数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To report renal outcomes including long-term patency, secondary interventions, and related renal function after fenestrated endovascular aortic repair (fEVAR). METHODS: Single-center retrospective review of patients undergoing fEVAR between 2012 and 2018 using the Cook ZFEN device. Renal stent complications, defined as any stenosis, occlusion, kink, renal stent-related endoleak, and reinterventions were tabulated. Estimated glomerular filtration rate (eGFR) was estimated using the Modification of Diet in Renal Disease formula. RESULTS: During the study period, 114 patients underwent elective fEVAR. Of 329 total target vessels, 193 renal arteries were stented (133 Atrium iCAST, 60 Gore VBX). Technical success was achieved in 97.4%, and the mean follow-up was 23.3 months. Seventeen renal complications occurred in 14 patients (12.3%), including 4 occlusions, 9 stenosis, 3 dislocations, and 1 type III endoleak. All stent complications underwent endovascular reintervention with a median hospital stay of 1 day (0-10) and a technical success of 94.2%. One patient suffered renal hemorrhage that warranted embolization. Patients with occlusion were treated the day of diagnosis, and mean time from diagnosis to intervention for stenosis was 21.5 days. Estimated primary patency was 92.1 % and 81.5% at 24 and 48 months, respectively. On multivariate analysis, larger native renal artery diameter was the only independent protective factor against patency loss (HR 0.23 (0.09-0.59)). Secondary patency at latest follow-up was 99.4%. Mean eGFR was not significantly different at latest follow-up between patients with renal complications versus those without (43.75 vs. 55.58 mL/min/1.73 m2, P = 0.09). Comparing patients with and without renal stent complications, 81.4% and 72.7% of patients had stable or improved renal disease by chronic kidney disease staging compared with baseline (P = 0.51). CONCLUSIONS: fEVAR is a durable option for the treatment of juxtarenal aortic aneurysms and is associated with excellent secondary patency. Renal stent complications have no significant impact on renal function, but smaller native renal arteries are at higher risk of stent-graft complications.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Deslarzes-Dubuis C, Tran K, Colvard BD, et al. Renal Stent Complications and Impact on Renal Function after Standard Fenestrated Endovascular Aneurysm Repair. Ann Vasc Surg. 2020. PMID: 33249133. doi:10.1016/j.avsg.2020.10.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。